Skip to main content

Table 1 Demographic and clinical characteristics at baseline

From: Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST)

Characteristic Budesonide (N = 48) Placebo (N = 43) p Value
Male sex - no. (%) 30 (62.5) 29 (67.4) 0.662
0.662 Median age (yrs) - Mean (SD) 53.1 + 12.2 52.0 + 12.9 0.660*
Duration of disease (mths) -Mean (SD) 23.4 + 33.4 15.4 + 15.4 0.139*
Complete remission pre-SZT - no. (%) 18 (38.3) 17 (40.5) 0.834
Basic disease - no. (%)    0.179
Myelodysplastic syndrome - MDS 5 (10.6) 7 (16.3)  
Acute myeloid leucemia - AML 19 (40.4) 14 (32.6)  
Acute lymphoblastic leucemia - ALL 7 (14.6) 4 (9.3)  
Chronic myeloid leucemia - CML 1 (2.1)   
Chronic lymphocytic leucemia - CLL 1 (2.1) 2 (4.7)  
Non Hodgkin lymphoma - NHL /M. Hodgkin 6 (12.8) 3 (7.0)  
Multiple myeloma 3 (6.4) 11 (25.6)  
Others 5 (10.6) 2 (4.7)  
Chemotherapeutic conditioning - no. (%) 44 (91.7) 36 (83.7) 0.246
Total body irradiation -TBI - no. (%) 27 (56.3) 22 (51.2) 0.627
Dosage reduced induction regimen (%) 27 (56.3) 24 (55.8) 0.967
In-vivo T-cell depletion (%) 29 (60.4) 26 (60.5) 0.994
Sibling transplant (%) 17 (35.4) 15 (34.9) 0.958
CMV-status positive - no. (%) 31 (64.6) 32 (74.4) 0.31
  1. 0.31P value based on a chi-square test or * t-test.